FDA to Require 50 Percent Efficacy for COVID-19 Vaccines
Vaccine experts divided on whether that level of protection is too low or too demanding.
Related Articles
Challenges in ageing persons with haemophilia
As treatments for individuals with inherited bleeding disorders improve, life expectancy increases and is approaching that of the normal population. Concomitant with this we are…
The importance and evolution of bleeding disorder registries
Registries are excellent sources of data to address questions that are typically not evaluated in randomized clinical trials, including natural history, disease prevalence, treatment approaches…
Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec
Abstract. The US Food and Drug Administration (FDA)’s authorization of etranacogene dezaparvovec (Hemgenix) is a significant milestone, constituting not on
The Application of AI to the Care of Thrombocytopenia
A video from Drew Provan (as part of XIV Eurasian Hematology-Oncology Congress – EHOC 2023), posted on Feb 14, 2024.
Type 1 VWD classification revisited: novel insights from combined analysis of the LoVIC and WiN studies
Age-dependent effects on plasma VWF levels in type 1 VWD define distinct subgroups with important differences in underlying pathogenesis.Low VWF does not c
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial
Subcutaneous emicizumab administered from birth has the potential to reduce the risk of ICH and joint bleeds before damage occurs.Primary analysis of the H
Guideline for laboratory diagnosis and monitoring of von Willebrand disease: A joint guideline from the United Kingdom Haemophilia Centre Doctors’ Organisation and the British Society for Haematology
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Management of Autoimmune, Viral and Surgical Associated Anti-PF4 Disorders
A video from Theodore Warkentin (as part of Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024), posted on Mar 19, 2024.
Guideline for laboratory diagnosis and monitoring of von Willebrand disease: A joint guideline from the United Kingdom Haemophilia Centre Doctors’ Organisation and the British Society for Haematology
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Low-dose emicizumab prophylaxis in patients with severe hemophilia A: a retrospective study bringing new hope for our patients
Low-dose emicizumab can potentially offer a cost-effective treatment option in persons with hemophilia A, especially in developing countries.